Lake Street Capital started coverage on shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) in a research report report published on Friday, MarketBeat.com reports. The firm issued a buy rating and a $18.00 price target on the stock.
A number of other equities research analysts have also recently commented on the company. HC Wainwright raised their price target on Sensus Healthcare from $10.00 to $11.00 and gave the company a "buy" rating in a report on Monday, November 18th. Maxim Group lifted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, November 15th.
Read Our Latest Stock Analysis on Sensus Healthcare
Sensus Healthcare Stock Performance
Shares of NASDAQ SRTS traded up $0.33 during midday trading on Friday, reaching $8.44. The stock had a trading volume of 412,803 shares, compared to its average volume of 250,444. The company has a market capitalization of $138.33 million, a price-to-earnings ratio of 14.81 and a beta of 1.24. Sensus Healthcare has a 12-month low of $2.91 and a 12-month high of $9.33. The stock has a 50-day moving average of $7.48 and a 200-day moving average of $6.86.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Truvestments Capital LLC bought a new position in Sensus Healthcare during the third quarter valued at approximately $32,000. IFP Advisors Inc bought a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $95,000. Cubist Systematic Strategies LLC bought a new position in shares of Sensus Healthcare during the 2nd quarter valued at approximately $156,000. Sigma Planning Corp purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $215,000. Finally, XTX Topco Ltd increased its position in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock worth $183,000 after purchasing an additional 13,619 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company's stock.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Articles
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
